MAKE IT STOP – a documentary about Ewing sarcoma by the Ewing Cancer Foundation of Canada – debuts scheduled for Richmond Hill ON (Sept 23), Labrador City (Sept 7), St John’s NL (Sept 17) and Fall River NS (Sept 23). Richmond Hill debut features live music by Tom Corrigan
MAKE IT STOP. A DOCUMENTARY.
You are cordially invited to celebrate the Debut of our most recent project. Through this important 45 minute documentary, we will share with you the history of Ewing sarcoma, stories of people affected and hear from doctors and researchers in Canada.
It will move, inspire and educate you!
September 23rd, 2017
Cosmo Music (Cosmopolitan Music Hall)
10 Via Renzo Drive
Richmond Hill, ON
Film screening will begin at 2:30
Refreshments and live music by Tom Corrigan
There is no charge for admission, however donations are greatly appreciated. Please say you’ll come and share this Debut experience with us. RSVP at firstname.lastname@example.org by September 1st.
We are also hosting Debuts in the following areas; contact email@example.com if you would like to attend.
- Labrador City- Sept. 7th
- ST. John’s NL Sept. 17th
- Fall River NS Sept. 23rd
Stay-tuned for funding and registration information for the C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop (04-Nov-2017, BC)
C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop will be held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year; members from all C17 DVL sites and PROFYLE clinical site leads are encouraged to attend.
The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.
The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.
If our fundraising is successful, our goal is to help provide some funding to C17 DVL participating centres to allow investigators and senior research staff to attend.
Registration will be live next week.
9th Annual Interaction Conference Sept 22-23 in Toronto: an integrated industry and academic conference targeted towards those who manage or direct projects related to oncology clinical trials (www.interaction-canada.ca)
On behalf of my fellow conference organizers, I would like to bring your attention to the ninth annual Interaction Conference – an Academic-Industry Cancer Trials meeting that will be held at the MaRS building in Toronto on September 22-23, 2017. The aim of this conference is to bring together cancer clinical trials staff from academia and pharma for a two day meeting. The meeting is being organized to cater to the needs of clinical trials staff, including project directors, project managers, CRAs, data coordinators, nurses, monitors, regulatory officers and administrators.
Important goals of this meeting are to foster closer cooperation and understanding between academia and pharma staff in the conduct of cancer studies.
Further information and a registration link can be found at www.interaction-canada.ca
Please pass along to others who may be interested. Do not hesitate to contact us with any questions.
I look forward to seeing you in September.
Jasmine Grant, MEd, CCRP
Education Specialist Lead
Cancer Clinical Research Unit
Princess Margaret Cancer Centre
(416) 946-4501 x3465
*PRIORITY FUNDING CALL: BioCanRx is pleased to announce that the next call for applications is now open in all of the Catalyst, Enabling, Clinical Trial, and Clinical, Social & Economic Impact (CSEI) programs. At this time, BioCanRx is placing highest priority on the intake of new applications for funding, proposing research activities that would be likely to add value to, facilitate the implementation of, or enhance the translation to clinic of, technologies within the existing BioCanRx portfolio of research investments. The projects contained within the BioCanRx research portfolio are found here. Of important note, new applications will be expected to speak very specifically to the value-add of their proposed research deliverables and the complementarity to support the successful development of BioCanRx technologies or research projects.
Funding timelines: Applicants should be aware that all projects must plan to be completed no later than March 31, 2020. Given this time constraint, it is unlikely that new clinical trial projects will be funded in this next call for proposals, unless the trial is of a small pilot scale AND the applicant(s) can convincingly demonstrate feasibility of completion of the study by March 31, 2020.
Application deadlines: Next LOI submission deadline will be 11:59 am EST on November 1, 2017 invited full applications are anticipated by mid-February (date TBD) for funding to commence by April 1, 2018.
The interactive reporting tools have now been deployed to the CCRA website as a submenu under Initiatives – Canadian Cancer Research Survey. Please note that the link that I forwarded previously is now retired.
The reports are available in both official languages.
Note that there are a few remaining issues with the French. First, the Tableau Public interface (where the dashboards are embedded) is in English. Second, the All selection in the filter lists does not appear as ‘Tous’. And finally, the numbers are not appropriately formatted. I’m hoping that I will eventually be able to resolve these issues, but for now, the data itself is available in French.
Please let me know if you have any questions or concerns and thank you for your patience with this project.
Kimberly Badovinac, MA, MBA
Manager, Canadian Cancer Research Survey / Directrice, Enquête canadienne sur la recherche sur le cancer
Canadian Partnership Against Cancer / Partenariat canadien contre le cancer
1 University Avenue, Suite 300, Toronto ON M5J2P1
Ph / Tél : (416) 619-6265
Kimberly.Badovinac@partnershipagainstcancer.ca / firstname.lastname@example.org
CTL019 CAR-T study now open at Sick Kids: Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients see: https://clinicaltrials.gov/ct2/show/NCT02228096
The August 2017 NAIT newsletter can be found HERE.
For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to email@example.com
Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung
BOOKMARK NAIT: The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html
HELPING FAMILIES NAVIGATE: To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.
The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.
CCO Call for Research Proposals – Analytics and Informatics ** DEADLINE: Friday, August 18th by 5 pm (EDT)
Analytics and Informatics (A&I) at CCO is calling for research proposals by investigators to undertake research projects in the priority areas of capacity planning, implementation projects and population health projects.
I encourage you to apply for a research grant by completing the attached application form. Please refer to the attached announcement for further details, including eligibility criteria. Applications are due by 5 pm (EDT) to the CCO Research Office (firstname.lastname@example.org).
Please feel free to share this with any researcher in Ontario within your network who might be interested in applying for a research grant. I appreciate your assistance.
Jason Garay BSc, BASc, MHSc
Analytics & Informatics
Adjunct Professor, University of Toronto
CCO | Our future health built with care
620 University Ave., Toronto, ON M5G 2L7
YOU HAVE BEEN MISSING OUT, if you are not a part of the CYP-C Research Champions program. [Video & Publication Opportunity]
YOU HAVE BEEN MISSING OUT, if you are not a part of the CYP-C Research Champions program. Please watch our [VIDEO] update and think about joining for opportunities to publish and more! [CYP-RC Publication Policy]
We also have a meeting booked at SIOP in Washington DC (Sunday, October 15 from 13:30 – 17:00), for those in attendance.
Have you discussed sub-fertility risk and fertility preservation options with your patients? Most cancer survivors report that fertility was not discussed with them at the time of their diagnosis.
The 2013 ASCO guidelines advocate that fertility should be discussed with all newly diagnosed cancer patients.
Did you know?
- Some patients and families mistakenly believe that all cancer therapies cause infertility.
- Sperm Banking is a proven intervention to preserve fertility in post pubertal males.
- Please go to the SickKids Fertility Preservation Website to down load our Sperm Banking informational Pamphlet. You are welcome to print of copies for your patients. www.sickkids.ca/fertility-preservation
- Fertile Future is a charity which helps support cancer patients afford the cost of Fertility Preservation. They can also help you connect to a fertility clinic in your region. fertilefuture.ca
- Need advice on supporting fertility preservation at your centre? Contact Anne Marie Maloney NP at email@example.com